ArticleInternational journal of molecular medicine2019
MicroRNA‑379‑5p suppresses renal fibrosis by regulating the LIN28/let‑7 axis in diabetic nephropathy.
Article in International journal of molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Total flavonoids ofPharmaceutical biology · 2026Article
- miR-379-5p serves as a biomarker and regulates sepsis-associated acute kidney injury via targeting EDN1.BMC immunology · 2026Article
- Association of GAS6, AXL, and GAS6-AS lncRNAs with nephropathy in Egyptian patients with type 2 diabetes mellitus: a case-control observational study.Nutrition & diabetes · 2025Observational
- miR-379-5p Inhibited the Proliferation of Acute Myeloid Leukemia Cells Through Negative Regulation ofTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- Article
- miR-379-5p retards the proliferation and differentiation of goat skeletal muscle satellite cells by targetingFrontiers in veterinary science · 2025Article
- Long non-coding RNA MEG3 silencing weakens high glucose-induced mesangial cell injury by decreasing LIN28B expression by sponging and sequestering miR-23c.Kidney research and clinical practice · 2024Article
- Dysregulated Urinary Extracellular Vesicle Small RNAs in Diabetic Nephropathy: Implications for Diagnosis and Therapy.Journal of the Endocrine Society · 2024Article
- Article
- MicroRNA-122-5p ameliorates tubular injury in diabetic nephropathy via FIH-1/HIF-1α pathway.Renal failure · 2022Article
- Targeting CC chemokine ligand (CCL) 20 by miR-143-5p alleviate lead poisoning-induced renal fibrosis by regulating interstitial fibroblasts excessive proliferation and dysfunction.Bioengineered · 2022Article
- LncRNA MALAT1 Aggravates Renal Tubular InjuryFrontiers in endocrinology · 2022Article
- Transcriptome reveals key microRNAs involved in fat deposition between different tail sheep breeds.PloS one · 2022Article
- Circ-FBXW12 aggravates the development of diabetic nephropathy by binding to miR-31-5p to induce LIN28B.Diabetology & metabolic syndrome · 2021Article
- Lin28a attenuates TGF-β-induced renal fibrosis.BMB reports · 2020Article
- Integrative microRNA and mRNA expression profiling in acute aristolochic acid nephropathy in mice.Molecular medicine reports · 2020Article
- MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application.International journal of molecular sciences · 2020Review
- Psoralen alleviates high glucose-induced HK-2 cell injury by inhibition of Smad 2 signaling via upregulation of microRNA 874.BMC pharmacology & toxicology · 2020Article
- Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease.Frontiers in pharmacology · 2020Review
- Noncoding RNAs in Diabetic Nephropathy: Pathogenesis, Biomarkers, and Therapy.Journal of diabetes research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs or miRs) play an important role in pathological processes in diabetic nephropathy (DN). This study aimed to explore whether miR‑379‑5p is associated with renal fibrosis in DN and to elucidate the underlying mechanisms. In vitro experiments indicated that miR‑379‑5p expression was downregulated by high glucose (HG) treatment in mouse mesangial cells (MMCs). Transfection with miR‑379‑5p mimics suppressed the proliferation and the accumulation of extracellular matrix (ECM) components, which were promoted by HG treatment. LIN28B was proven to be a direct target of miR‑379‑5p by luciferase report assay. In addition, the loss of expression of LIN28B, as well as the decrease in cell proliferation and in the accumulation of ECM components, which were induced by the knockdown of LIN28B, were attenuated in the MMCs following transfection with miR‑379‑5p inhibitors. Furthermore, type 2 diabetic db/db mice were used to examine the efficiency of miR‑379‑5p agomir in the alleviation of renal fibrosis. Consistent with the results of the in vitro experiments, miR‑379‑5p agomir suppressed mesangial cell proliferation and the accumulation of ECM components by regulating the LIN28B/let‑7 pathway. Taken together, the findings of this study suggest that miR‑379‑5p is highly involved in renal fibrosis in DN, and that it may be a potential effective therapeutic target for DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.